| Overview |
| bs-9250R-RBITC |
| RNF125 Polyclonal Antibody, RBITC Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TRAC1/RNF125 |
| 1-100/232 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9611 |
| T cell RING activation protein 1; E3 ubiquitin protein ligase RNF125; Ring finger protein 125; RNF 125; T cell ring protein identied in activation screen; TRAC 1; TRAC1; RN125_HUMAN. |
| The RING-type zinc finger motif is present in a number of viral and eukaryotic proteins and is made of a conserved cysteine-rich domain that is able to bind two zinc atoms. Proteins that contain this conserved domain are generally involved in the ubiquitination pathway of protein degradation. TRAC-1 (T-cell RING activation protein 1), also known as RNF125 (ring finger protein 125) or E3 ubiquitin-protein ligase RNF125, is a 232 amino acid novel E3 ubiquitin ligase that functions as a positive regulator in the T-cell receptor signaling pathway. Expressed predominantly in lymphoid tissues such as spleen, thymus and bone marrow, TRAC-1 has been found to inhibit pathogen-induced cytokine production and down-regulates HIV replication. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz